{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:21Z","timestamp":1753892001399,"version":"3.41.2"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Anaplastic lymphoma kinase (ALK) inhibitor alectinib has demonstrated significant potential in treating non-small cell lung cancer (NSCLC); however, its adverse effects remain a notable challenge for healthcare professionals. This report examines the case of a 79-year-old female lung cancer patient who presented with persistent colic in the left abdomen 10 months after initiating alectinib treatment. Upon admission, abdominal computed tomography revealed mild thickening of the descending colon wall, accompanied by free gas and surrounding exudation, leading to a diagnosis of descending colon perforation. After excluding alternative causes of gastrointestinal perforation, the condition was attributed to a severe adverse reaction associated with alectinib. While alectinib has been reported to cause serious gastrointestinal perforations, the underlying mechanism remains unclear and warrants further clinical investigation. Clinicians should be vigilant in recognizing and promptly managing this potential complication during alectinib therapy.<\/jats:p>","DOI":"10.3389\/fphar.2025.1545614","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:10:53Z","timestamp":1747800653000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yun","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"volume-title":"Alecensa","year":"2021","key":"B1"},{"key":"B2","doi-asserted-by":"publisher","first-page":"100319","DOI":"10.1016\/j.ctarc.2021.100319","article-title":"Revisiting a lower starting dose of alectinib in ALK-Positive non-small cell lung cancer","volume":"27","author":"Dbsa","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jdcr.2020.09.007","article-title":"Alectinib-associated drug reaction with eosinophilia and systemic symptoms syndrome","volume":"6","author":"Farooq","year":"2020","journal-title":"JAAD Case Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/j.cllc.2020.06.021","article-title":"Successful drug rechallenge following severe acute alectinib-induced interstitial lung disease in a patient with advanced ALK-rearranged lung adenocarcinoma","volume":"22","author":"Gadotti","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2016.06.012","article-title":"Gastrointestinal perforations in patients treated with erlotinib: a report of two cases with fatal outcome and literature review","volume":"99","author":"Gass-J\u00e9gu","year":"2016","journal-title":"Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/cup.13911","article-title":"Cutaneous sarcoid like drug reaction caused by an anaplastic lymphoma kinase inhibitor","volume":"48","author":"Gleue","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00432-008-0424-0","article-title":"Gastrointestinal metastasis of lung cancer with special emphasis on a long-term survivor after operation","volume":"135","author":"Kim","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.21037\/tlcr-20-564","article-title":"Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK rearranged non-small cell lung cancer: a case series","volume":"10","author":"Myall","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"omy009","DOI":"10.1093\/omcr\/omy009","article-title":"Progressive renal insufficiency related to ALK inhibitor, alectinib","volume":"2018","author":"Nagai","year":"2018","journal-title":"Oxf Med. Case Rep."},{"key":"B10","unstructured":"The NCCN non-small cell lung cancer clinical practice guidelines in oncology (version 1.2022)\n          \n          \n          2022"},{"key":"B11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2169\/internalmedicine.4241-19","article-title":"Alectinib induced immune hemolytic anemia in a patient with lung adenocarcinoma","volume":"60","author":"Okumoto","year":"2021","journal-title":"Intern Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13256-018-1849-y","article-title":"Alectinib (Alecensa) induced reversible grade IV nephrotoxicity: a case report and review of the literature","volume":"12","author":"Ramachandran","year":"2018","journal-title":"J. Med. Case Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1177\/1078155220904141","article-title":"Life-threatening hypertriglyceridemia induced pancreatitis related to alectinib successfully treated by plasmapheresis: a review of the literature on metabolic toxicities associated with anaplastic lymphoma kinase inhibitors","volume":"26","author":"Rao","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X20966895","article-title":"Patients with high-grade alectinib-induced skin rash: how do we desensitize these patients? a case report and review of literature. SAGE Open Med Case Rep","volume":"8","author":"Seegobin","year":"2020"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.2147\/OTT.S136837","article-title":"Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction","volume":"10","author":"Shimada","year":"2017","journal-title":"Onco Targets Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.2169\/internalmedicine.8214-16","article-title":"Crizotinib-induced rectal perforation with abscess","volume":"56","author":"Yanagisawa","year":"2017","journal-title":"Intern Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjh.16813","article-title":"Two cases of marked red cell anisopoikilocytosis and haemolysis with alectinib, an anaplastic lymphoma kinase inhibitor","volume":"190","author":"Yuan","year":"2020","journal-title":"Br. J. Haematol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1545614\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:10:57Z","timestamp":1747800657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1545614\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":17,"alternative-id":["10.3389\/fphar.2025.1545614"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1545614","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"1545614"}}